NCT03332498 2022-06-03
Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
H. Lee Moffitt Cancer Center and Research Institute
University of California, San Francisco
Royal Marsden NHS Foundation Trust
Pharmacyclics LLC.